Clinical Trials Directory

Canary Prostate Active Surveillance Study

The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.

Stanford is now accepting new patients for this trial. Please contact Michelle Ferrari at 650-725-5543 for more information.


Phase: N/A


Ages Eligible For Study:

21 Years - N/A

Inclusion Criteria

- Histologically confirmed adenocarcinoma of the prostate. - Clinically localized prostate cancer: T1-2, NX or N0, MX or M0. - No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy). - ECOG Performance Status 0 or 1. - Patient has elected Active Surveillance as preferred management plan for prostate cancer. - Patient consent has been obtained according to local Institutional Review Board for acquisition of research specimens. - Patient is accessible and compliant for follow-up. - Prostate biopsy requirements: 1. If diagnosis was within one year of baseline visit, participant must have at least one biopsy with at least 10 cores. 2. If diagnosis was more than 1 year prior to baseline visit, participant must have a minimum of 2 biopsies, one of which must be within 2 years prior to baseline visit.

External Links

Explore related trials

Contact information

Primary Contact:

Michelle Ferrari 650-725-5543

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: